

Thyroid Disorders and Brain Natriuretic Peptide

Hamiyet Yılmaz^{1*}, Barış Pamuk²,
Derun Taner Ertugrul³ and Erdem Yaşar⁴

¹*Aydın State Hospital, Department of Endocrinology and Metabolism*

²*Bozyaka Training and Research Hospital, Department of Internal Medicine*

³*Kecioren Training and Research Hospital, Department of Internal Medicine*

⁴*Acipayam State Hospital, Department of Anaesthesia
Turkey*

1. Introduction

The structure of atrial natriuretic peptide (ANP) was first discovered in 1984 (1). In following years, a molecule, which resembled ANP, was isolated from a pig brain (2). This B-type or brain natriuretic peptide (BNP) is a member of the natriuretic peptide family that has physiological effects similar to atrial natriuretic peptide (ANP), including diuretic, natriuretic, and vasorelaxant actions (3,4). Although this peptide is referred to as the brain natriuretic peptide (BNP), it is actually produced in the ventricular myocardium (5). BNP is not a prestored molecule, but if proper stimuli exist it can be produced rapidly through mRNA synthesis. The stimulus triggering the secretion of BNP by the ventricles of the heart is mainly excessive stretching of myocytes rather than the transmural pressure load (6-8). BNP is synthesized both in an inactive N-terminal fragment with 76 amino acids (NTpro-BNP) and an active hormone with 32 amino acids (BNP). ANP and related precursor peptides comprise 98% of all natriuretic peptides in healthy subjects (9).

Like ANP, BNP is induced by pathophysiological conditions of the heart, including hypertrophy, myocardial infarction, and heart failure. BNP levels have been shown to be a good predictor of left ventricular dysfunction and decompensated heart failure, and recently BNP infusion has been approved as an effective treatment for acute heart failure (10,11). Distinct physiological roles of BNP have been elucidated by generation of knockout (KO) mice. While BNP KO mice are no different from control mice with regard to blood pressure, urine volume, and urinary Na⁺ and K⁺ excretion, they have more extensive ventricular fibrosis, accompanied by increased transforming growth factor-3 (TGF-3) and collagen mRNA [81]. Studies of cultured cells indicate that BNP inhibits growth of vascular cells, as well as fibroblast proliferation and collagen production by fibroblasts (3,12). Thus, BNP may function more as an autocrine/paracrine inhibitor of cell growth in the heart, while ANP

* Corresponding Author

functions more as a traditional circulating hormone with pronounced diuretic, natriuretic, and anti-hypertensive effects. (3)

In addition to ventricular myocardium, extracardiac sources of BNP have been detected in tissues at autopsy, including the lungs, kidneys, and adrenal glands, although at much lower levels than ventricular BNP (13). BNP is produced, to a small degree, by the renal glomerular epithelial and mesangial cells (14,15) is a counter-regulatory hormone that physiologically opposes and suppresses the renin-angiotensin aldosterone system (RAAS), endothelin-1 and the sympathetic nervous system (SNS). Endogenous BNP and ANP production maintain renal function and sodium balance when cardiac function acutely deteriorates (16).

Routine BNP testing has recently been introduced as a noninvasive, low-risk test that measures circulating levels of BNP, which are elevated in individuals with both symptomatic and asymptomatic heart failure. The BNP test is used to detect preclinical heart disease or to confirm the cardiac etiology in symptomatic patients. It not only enables the early identification of patients with incipient heart failure but also provides prognostic information based on the magnitude of the increase. Also administration of exogenous intravenous (IV) BNP shown to rapidly improve hemodynamic, volume, neurohormonal, and symptomatic abnormalities in patients with acute decompensated heart failure and to decrease rates of rehospitalization (17,18). Nesiritide IV (human recombinant BNP) is approved for the treatment of acute decompensated CHF. The physiologic effects of nesiritide include veno- and arterial dilatation (without reflex tachycardia), diuresis, and natriuresis (without reduction in renal perfusion or function). Thus, nesiritide increases cardiac index and reduces pulmonary capillary wedge pressure (PCWP) (18). In addition, nesiritide is lusitropic, anti-fibrotic, and inhibits RAAS; thus, nesiritide should stabilize renal function acutely and chronically while improving cardiac function and hemodynamics in CHF patients.

The cardiovascular system is very sensitive to thyroid hormones. Hyperthyroidism and hypothyroidism induce significant changes in cardiac functions. The effects of hyperthyroidism on the heart include hemodynamic changes such as decreased systemic vascular resistance as well as increased cardiac output, heart rate, blood volume, blood pressure and impaired cardiac contractility. It may also lead to atrial arrhythmias (19). These changes result in ventricular stretch and pressure overload, which might cause concomitant rise in BNP concentrations (20). Recent attention has been drawn to the relation of BNP and hyperthyroidism. Studies suggest that plasma BNP and NT-pro-BNP concentrations are frequently increased in hyperthyroidism. This increase is partly due to hyperthyroidism-induced left ventricular dysfunction. Also in vitro animal studies have suggested that T4 and T3 stimulate BNP release from both cultured atrial and ventricular myocytes (21).

There are only a limited number of studies with contradictory results investigating the effect of thyroid function abnormalities on the measurement of BNP. Wei et al. have measured the BNP levels and left ventricular functions of 67 hyperthyroid patients and 32 healthy subjects. The average BNP level was found to be higher in the patients especially the ones with left ventricular dysfunction than the healthy individuals. Nonsignificant correlations between thyroid hormones and BNP levels were identified (19). Biondi et al. demonstrated

an increase of left ventricular mass more specifically, an increase of septal and posterior wall thickness, enhanced resting systolic function and significantly impaired Doppler parameters of diastolic function (22). Smit et al. demonstrated that diastolic dysfunction was impaired in exogenous subclinical hyperthyroidism induced by levothyroxine treatment in 25 differentiated thyroid carcinoma patients (23). Two small studies suggest a beneficial effect of treatment of subclinical hyperthyroidism on cardiac function (24,25). Schultz et al. studied NT-pro-BNP levels in different thyroid function states and found that serum levels of NT-pro-BNP were strongly affected by thyroid function; the higher the thyroid function, the higher the serum levels of NT-pro-BNP. Likewise the treatment of the dysthyroid state resulted in a significant increase in NT-pro-BNP in both overt and subclinical hypothyroid patients and a decrease in both overt and subclinical hyperthyroid patients. In order to evaluate whether those findings were the direct effect of thyroid hormones or were the results of changes in heart function and structure, they compared NT-pro-BNP, thyroid function and cardiac output (CO) or resting pulse rate in a subgroup of patients under study. CO or resting pulse rate did not have any independent effect on NT-pro-BNP levels, whereas, thyroid function had a significant effect on NT-pro-BNP levels (26). Ertugrul et al evaluated the serum BNP levels in 18 overt and 47 subclinical hyperthyroid patients together with 39 subclinical and 13 overt hypothyroid patients. BNP levels were more than five times higher in hyperthyroid than euthyroid control subjects. BNP levels were also higher in subclinical hyperthyroidism than euthyroid control subjects. Free T4 and free T3 concentrations were found to be associated with high serum BNP levels. The BNP level in patients with subclinical or overt hypothyroidism was similar to that of the controls (27). On the other hand, Christ-Crain et al. found that there was no significant difference in NT-proBNP levels of euthyroid and overt hypothyroid, subclinical hypothyroid and subclinical hyperthyroid subjects, and NT-pro-BNP levels were higher in overt hyperthyroidism compared to other groups (9). Kohno et al. have found higher BNP levels in untreated hyperthyroid patients and rats with hyperthyroidism induced by thyroxine than their normal counterparts. Hypothyroid rats had lower plasma BNP concentration than the euthyroid ones. In-vitro effects of T3 and T4 on the release of BNP were investigated in newborn rat atrial and ventricular myocytes in primary culture. T3 and T4 stimulated release of BNP from both cultured atrial and ventricular myocytes in a dose-dependent manner (21). Triiodothyronine also increases BNP gene transcription and amplifies endothelin-dependent BNP gene transcription in rat ventricular myocytes (28). The effect of hyperthyroidism and subclinical hyperthyroidism on the heart may also cause an increase in BNP. At the moment, we do not know which one of these mechanisms is actually responsible for alterations in BNP levels in thyroid dysfunction. There is little known about the effects of endogenous subclinical hyperthyroidism on the heart. Faber et al. demonstrated an increase in cardiac output and a reduction in total peripheral resistance when treating subclinical hypothyroid subjects with L-T4, whereas the opposite is seen on treating subclinical hyperthyroidism with radioiodine (24).

Ertugrul et al studied BNP levels in patients with hyperthyroidism before specific treatment for hyperthyroidism and after euthyroidism was achieved. This study showed that BNP levels were significantly higher in hyperthyroid than euthyroid status of the same patients. It was found that the decrease in BNP levels was positively correlated with the decrease in fT3 and fT4 (29). Kato et al measured serum ANP and BNP levels in 130

patients with thyrotoxicosis and correlated them with serum thyroid hormone levels and with the degree of severity of the heart failure. They reported a significant elevation of BNP and atrial natriuretic peptide levels which returned to normal values after euthyroidism was established in patients with thyrotoxicosis. It was concluded that both serum thyroid hormones and cardiovascular dysfunction contribute to the increase of serum BNP levels and atrial fibrillation is an independent contributing factor for the increase of BNP (30).


In conclusion, natriuretic peptide levels are altered in different thyroid states with a more pronounced effect in hyperthyroidism compared to hypothyroidism. This seems to reflect distinct atrial and ventricular cardiac dysfunction in thyroid hormone excess or, alternatively, mirrors a direct effect of thyroid hormones on gene expression of natriuretic peptides. As hyperthyroidism results in increased serum levels of pro-ANP, NT-proBNP and BNP levels as typically seen in mild heart failure, hyperthyroidism should be considered in patients presenting with unclear symptoms and mildly elevated natriuretic peptide levels (9). Since the treatment of hyperthyroidism is quite different than the treatment of heart failure, thyroid hormones should be checked in patients with high levels of BNP. Mild elevations in NT-pro-BNP levels should therefore always be accompanied by a thyroid function screening test (26,29).

2. References

- [1] Kangawa K, Fukuda A, Minamino N, et al. Purification and complete amino acid sequence of beta-rat atrial natriuretic polypeptide (betarANP) of 5000 daltons. *Biochem Biophys Res Commun*. 1984;119:933-940.
- [2] Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. *Nature*. 1988;332:78-81.
- [3] LaPointe MC. Molecular regulation of the brain natriuretic peptide gene. *Peptides* 2005; 26: 944-956.
- [4] Levin ER, Gardner DG, Samson WK. Natriuretic peptides. *N Engl J Med* 1998;339:321-8.
- [5] Hosoda K, Nakao K, Mukoyama M, et al. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. *Hypertension*. 1991;17:1152-1155.
- [6] Bruneau BG, Piazza LA, de Bold AJ. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. *Am J Physiol*. 1997;273:2678-686.
- [7] Wiese S, Breyer T, Dragu A, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. *Circulation*. 2000;102:3074-3079.
- [8] Mizuno Y, Yoshimura M, Harada E, et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. *Am J Cardiol*. 2000; 86:1036-1040.
- [9] Christ-Crain M, Morgenthaler NG, Meier C, et al. Pro-A-type and N-terminal pro-B-type natriuretic peptides in different thyroid function states. *Swiss Medical Weekly*. 2005;135:549-554.
- [10] Richards AM, Lainchbury JG, Nicholls MG, Troughton RW, Yandle TG. BNP in hormone-guided treatment of heart failure. *Trends Endocrinol Metab* 2002;13:151-5.

- [11] Latini R, Masson S, de Angelis N, Anand I. Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. *J Card Fail* 2002;8:288-99.
- [12] Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. *Circ Res* 2002;91:1127-34.
- [13] Gerbes AL, Dagnino L, Nguyen T, Nemer M. Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. *J Clin Endocrinol Metab* 1994;78:1307-11.
- [14] McCullough PA, Joseph K, Mathur VS. Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. *Rev Cardiovasc Med* 2004;5(1):16-25.
- [15] Lai KN, Leung JC, Yandle TG, et al. Gene expression and synthesis of natriuretic peptides by cultured human glomerular cells. *J Hypertension*. 1999;17:575-583.
- [16] Silver M, Horton D, Ghali J, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. *J Am Coll Cardiol*. 2002;39:798-803.
- [17] Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. *J Card Fail*. 1998;4:37-44.
- [18] Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study group. *N Engl J Med*. 2000;343:246-253.
- [19] Wei T, Zeng C, Tian Y, et al. B-type natriuretic peptide in patients with clinical hyperthyroidism. *J Endocrinol Invest*. 2005;28:8-11.
- [20] Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. *Circulation*. 1997;96:509-516.
- [21] Kohno M, Horio T, Yasunari K, et al. Stimulation of brain natriuretic peptide release from the heart by thyroid hormone. *Metabolism* 1993, 42:1059-64.
- [22] Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. *J Clin Endocrinol Metab*. 2000;85:4701-4705.
- [23] Smit JW, Eustatia-Rutten CF, Corssmit EP, et al. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. *J Clin Endocrinol Metab*. 2005;90:6041-6047.
- [24] Faber J, Wiinberg N, Schifter S, et al. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. *Eur J Endocrinol*. 2001;145:391-396.
- [25] Sgarbi JA, Villaca FG, Garbeline B, et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. *J Clin Endocrinol Metab*. 2003;88:1672-1677.
- [26] Schultz M, Faber J, Kistorp C, et al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. *Clin Endocrinol (Oxf)*. 2004;60:54-59.

- [27] Ertugrul DT, Gursoy A, Sahin M, Unal AD, Pamuk B, Berberoglu Z, Ayturk S, Tutuncu NB, Demirag NG. (2008) Evaluation of brain natriuretic peptide levels in hyperthyroidism and hypothyroidism. *J Natl Med Assoc* 100(4): 401-5.
- [28] Liang F, Webb P, Marimuthu A, et al. Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelindependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes. *J Biol Chem.* 2003;278:15073-15083.
- [29] Ertugrul DT, Yavuz B, Ata N, Yalçın AA, Küçükazman M, Algül B, Dal K, Akın KO, Deveci OS et al. Decreasing Brain Natriuretic Peptide Levels after Treatment for Hyperthyroidism. *Endocrine Journal* 2009, 56 (9), 1043-1048.
- [30] Kato K, Murakami H, Isozaki O, Tsushima T, Takano K. Serum concentrations of ANP and BNP in patients with thyrotoxicosis. *Endocrine Journal* 2009, 56 (1), 17-27.



Hypothyroidism - Influences and Treatments

Edited by Dr. Drahomira Springer

ISBN 978-953-51-0021-8

Hard cover, 348 pages

Publisher InTech

Published online 08, February, 2012

Published in print edition February, 2012

Hypothyroidism is the most common thyroid disorder and it is significantly more frequent than presented - millions of people suffer from this disease without knowing it. People with this condition will have symptoms associated with slow metabolism. Estimates of subclinical hypothyroidism range between 3 to 8 %, increasing with age, whereas it more likely affects women than men. About 10% of women may have some degree of thyroid hormone deficiency. Hypothyroidism may affect lipid metabolism, neurological diseases or other clinical conditions. The book includes studies on advancements in diagnosis, regulation and replacement therapy, thyroid ultrasonography and radioiodine therapy for hypothyroidism. "Hypothyroidism - Influences and Treatments" contains many important specifications, results of scientific studies and innovations for endocrine practice.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Hamiyet Yılmaz, Barış Pamuk, Derun Taner Ertugrul and Erdem Yaşar (2012). Thyroid Disorders and Brain Natriuretic Peptide, Hypothyroidism - Influences and Treatments, Dr. Drahomira Springer (Ed.), ISBN: 978-953-51-0021-8, InTech, Available from: <http://www.intechopen.com/books/hypothyroidism-influences-and-treatments/thyroid-disorders-and-brain-natriuretic-peptide>

INTECH

open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.